Tempest Therapeutics (TPST) Enterprise Value (2011 - 2026)
Tempest Therapeutics (TPST) posted Enterprise Value of -$7.7 million for Q4 2025, down 2.76% sequentially from -$7.5 million in Q3 2025, and up 74.54% YoY from -$4.4 million in Q4 2024.
Tempest Therapeutics (TPST) Enterprise Value (2011 - 2026) Analysis & Trends
Tempest Therapeutics has reported Enterprise Value for 15 years, with the latest figure at -$7.7 million in Q4 2025.
- Quarterly Enterprise Value rose 74.54% year-over-year to -$7.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.7 million (up 74.54% YoY) and the FY2025 annual result came in at -$7.7 million, up 74.54% from the prior year.
- Enterprise Value retreated to -$7.7 million in Q4 2025 per TPST's latest filing, from -$7.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$7.5 million in Q3 2025 and troughed at -$68.5 million in Q2 2021.
- A 5-year average of -$36.8 million and a median of -$31.4 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2021 and 2023: Enterprise Value sank 268.16% in 2021, then jumped 80.83% in 2023.
- Over 5 years, Enterprise Value stood at -$66.8 million in 2021, then surged by 52.6% to -$31.7 million in 2022, then declined by 23.83% to -$39.2 million in 2023, then grew by 22.84% to -$30.3 million in 2024, then jumped by 74.54% to -$7.7 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$7.7 million, -$7.5 million, and -$14.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | -800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -800,000.00 |
| Dec 31, 2025 | -7.71 Mn |
| Sep 30, 2025 | -7.50 Mn |
| Jun 30, 2025 | -14.28 Mn |
| Mar 31, 2025 | -21.51 Mn |
| Dec 31, 2024 | -30.27 Mn |
| Sep 30, 2024 | -22.10 Mn |
| Jun 30, 2024 | -31.10 Mn |
| Mar 31, 2024 | -32.30 Mn |
| Dec 31, 2023 | -39.23 Mn |
| Sep 30, 2023 | -11.12 Mn |
| Jun 30, 2023 | -17.60 Mn |
| Mar 31, 2023 | -23.38 Mn |
| Dec 31, 2022 | -31.68 Mn |
| Sep 30, 2022 | -57.99 Mn |
| Jun 30, 2022 | -66.62 Mn |
| Mar 31, 2022 | -60.75 Mn |
| Dec 31, 2021 | -66.83 Mn |
| Sep 30, 2021 | -59.76 Mn |
| Jun 30, 2021 | -68.46 Mn |